Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Morphosys Ag ADR (MOR)

Morphosys Ag ADR (MOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
MorphoSys AG Reports First Quarter 2023 Financial Results

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2023 .

MOR : 18.64 (-0.27%)
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), and Incyte (Nasdaq: INCY) today announced final five-year follow-up data from the Phase 2 L-MIND study showing that...

MOR : 18.64 (-0.27%)
INCY : 65.19 (-1.03%)
Why Shares of MorphoSys Are Up Wednesday

The company's phase 3 trial for a lead therapy is ahead of schedule.

MOR : 18.64 (-0.27%)
MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.

MOR : 18.64 (-0.27%)
MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results

Conference call and webcast (in English) tomorrow, November 17, 2022, at 2:00pm CET (1pm GMT/8:00am ET)

MOR : 18.64 (-0.27%)
CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

/PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of...

MOR : 18.64 (-0.27%)
TEVA : 16.98 (+1.01%)
MorphoSys AG (MOR) Q2 2022 Earnings Call Transcript

MOR earnings call for the period ending June 30, 2022.

MOR : 18.64 (-0.27%)
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results

Conference call and webcast (in English) tomorrow, August 4, 2022, at 2:00pm CEST (1pm BST/8:00am EDT)

MOR : 18.64 (-0.27%)
Devon Energy Produces A Record Quarter, Dividend Raised By 22%

Devon Energy produced another record quarter of profits, as higher volumes and prices provided significant tailwinds to results.

MOR : 18.64 (-0.27%)
DVN : 46.80 (-1.97%)
OXY : 61.21 (-3.04%)
MRO : 28.28 (-1.53%)
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 26, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today reported preliminary U.S. net product sales of Monjuvi® (tafasitamab-cxix) for the second quarter 2022 and...

MPSYF : 73.2700 (+2.10%)
MOR : 18.64 (-0.27%)

Barchart Exclusives

1 Reliable Dividend Stock to Buy at a Discount This July
Here’s a dividend-paying gem trading at an attractive valuation, which investors can consider this July while it's still a bargain. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar